loading page

Bosutinib-Induced Interstitial Lung Disease and Pleural Effusion: A Case Report and Literature Review
  • Qiuying Liu,
  • Nour Assad,
  • Cecilia Arana Yi
Qiuying Liu
University of New Mexico
Author Profile
Nour Assad
University of New Mexico
Author Profile
Cecilia Arana Yi
University of New Mexico Cancer Center
Author Profile

Abstract

Bosutinib is a tyrosine kinase inhibitor (TKI) approved for the management of chronic myeloid leukemia (CML). TKIs are associated with pulmonary complications but are rarely described with bosutinib. Here, we report the first description of bosutinib-induced interstitial lung disease and pleural effusion, which resolved after the discontinuation of bosutinib.

Peer review status:ACCEPTED

10 Apr 2020Submitted to Clinical Case Reports
11 Apr 2020Submission Checks Completed
11 Apr 2020Assigned to Editor
26 Apr 2020Reviewer(s) Assigned
29 Apr 2020Review(s) Completed, Editorial Evaluation Pending
30 Apr 2020Editorial Decision: Revise Minor
25 May 20201st Revision Received
25 May 2020Submission Checks Completed
25 May 2020Assigned to Editor
27 May 2020Review(s) Completed, Editorial Evaluation Pending
31 May 2020Reviewer(s) Assigned
09 Jun 2020Editorial Decision: Accept